Moleculin Biotech, Inc.
corporate_fare Company Profile
Moleculin Biotech, Inc. (NASDAQ:MBRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 61 items for MBRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for MBRX spans 10-Q, 8-K, DEF 14A, 424B5.
Recent high-impact activity:
- Moleculin Posts Wider-Than-Expected $9.59/Share Loss as Cash Runs Thin
- Moleculin 10-Q: $7.3M Cash, Going Concern Doubt, Nasdaq Exception to March 15, 2027
- Moleculin's Annamycin Interim Data Accepted for ASH; DMC Clears Trial to Continue
- Annamycin Arms Show 43% and 36% Remission vs 12% Placebo in Pivotal AML Trial
- Moleculin Completes Part A Dosing in Pivotal MIRACLE AML Trial; Data Due Q1 2027
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 54,541 shares in MBRX as of the October 30, 2026 settlement, a 56.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 13, 2026, 41.2% of MBRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for MBRX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-21.
ATM Offering Size Increased · Shares Sold Under ATM
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →